Navigation Links
Recurrence of aggressive uterine cancer reduced by new form of therapy

The incidence of uterine papillary serous carcinoma (UPSC) has increased since it was first identified in 1981. The condition was initially regarded as easy to treat until about 1990 when a number of persons were diagnosed with the // aggressive cancer. It has remained a significant problem since then.

UPSC is found in higher rates in African American women than in white women. The disease looks like ovarian cancer and spreads just as rapidly, restricting the choice of treatment to only chemotherapy.

A state-of-the-art treatment program now developed at Yale School of Medicine has been found to increase survival from the aggressive uterine papillary serous carcinoma (UPSC) sparing the need for additional therapy in some patients.

According to the study, it has been that a combination of platinum-based chemotherapy and vaginal radiation to be the most effective treatment for the disease. This has infact led to the establishment of a standard of care being established for this type of uterine cancer.

Moreover, it can also be used to evaluate the need for additional treatment following surgery and hence determine the prognosis. The survival rates of women have considerably increased with reduction in the recurrence rates.

The study was conducted on a group of 74 patients with UPSC who underwent complete surgical staging, or hysterectomy with removal of lymph nodes and fat pads. Cancer recurred in 43 percent of early stage patients who did not receive chemotherapy, while in the 20 percent of patients who received platinum-based chemotherapy there were no recurrences. About 14 patients were spared additional radiation treatment.
'"/>




Page: 1

Related medicine news :

1. Lowering Risk of Breast Cancer Recurrence
2. HRT Found To Increase Recurrence of Breast Cancer
3. The Link Between HRT And Recurrence of Breast Cancer
4. Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available
5. Predicting Breast Cancer Recurrence By Understanding Gene Signature
6. Combination Therapy To Avoid Prostate Cancer Recurrence
7. Cervical Cancer Recurrence Risk Even After Removal Of Pre-Cancerous Cells
8. Drugs Are Effective In Treating Depression and Preventing Recurrence
9. PET-CT Scores High On Precision for Diagnosing Ovarian Cancer Recurrence
10. Experts Warn of Bird Flu Recurrence in Maharashtra
11. Petition On Recurrence Of Dengue And Malaria In Kolkata
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... New York (PRWEB) , ... May 23, 2017 ... ... NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide ... Institute in Ft. Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... Orbita’s ... on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and IoT: ... Connected Home Event hosted by Parks Associates, a market research and consulting firm ...
(Date:5/23/2017)... San Francisco, California (PRWEB) , ... May 23, 2017 , ... ... released results of its new survey in an infographic on the current state of ... 900 U.S. respondents, familiar with anxiety, was conducted in April 2017 and benchmarked general ...
(Date:5/22/2017)... Kisco, NY (PRWEB) , ... May 22, 2017 , ... ... are urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics ... be administered for a variety of treatments. One or more sedation methods may be ...
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)...  The Corporate Whistleblower Center says, "We are ... clinics to call us anytime at 866-714-6466 if they ... in a substantial scheme to overbill Medicare. We ... employee of a medical equipment company if their ... medical practice groups with extra generous incentives to use, ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: